This CME-accredited, interactive webcast aims to support multidisciplinary collaboration during the diagnosis and management of patients living with Duchenne Muscular Dystrophy, and covers timely diagnosis, and recommendations to enhance DMD treatment strategies, ensure continuity of care, and establish effective patient monitoring.
Register to access
Tell others what you are learning about
Share this content with a colleague or friend
General Information
Title: Shaping the future of DMD: collaborative approaches to refining care
Jointly provided by Postgraduate Institute for Medicine and Springer Healthcare IME
This activity is supported by an independent educational grant from Pfizer
Release date: July 30th 2024
Expiration date: July 30th 2025
Estimated time to complete activity: 1 hour
Target Audience
This activity is intended for pediatric neurologists, primary care physicians, pediatricians, geneticists, genetic counselors, neuromuscular specialists, nurse practitioners, pulmonologists, cardiologists, endocrinologists, orthopedists and physical therapists engaged in the care of patients with duchenne muscular dystrophy.
Educational Objectives
After completing this activity, the participant should be better able to:
- Identify the common signs and symptoms of DMD to initiate treatment timely
- Integrate novel strategies to enhance multidisciplinary collaboration during patient management
- Discuss recommendations to enhance DMD treatment strategies, ensure continuity of care, and establish effective patient monitoring
Faculty
- Laurent Servais
Professor of paediatrics neuromuscular diseases at the University of Oxford and invited Professor at the University of Liege - Zoya Alhaswani
Consultant paediatrician with interest in neuromuscular disorders - Sam Geuens
Pediatric neuropsychologist - Jaqui Russell
Genetic and metabolic nurse practitioner, Sydney Children’s Hospital, Australia - Dovilė Dovidavičiūtė
Patient carer, Lithuania
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:
- Laurent Servais
Grants funding from Roch, Biogen, Novartis, Sysnav, Zentech, Scholar Rock, BioHaven Consulting fees from Roche, Biogen-Novarti, Sysnav, Zentech, Scholar Rock, BioHaven, Pfizer, Sarepta, Dyne, Astellas, Cerebral Therapeutics, Illumina, Altana
- Zoya Alhaswani
Consultant/Advisory Board for Roche - Sam Geuens
Nothing to disclose - Jaqui Russell
Nothing to disclose - Dovilė Dovidavičiūtė
Nothing to disclose
The PIM planners and others have nothing to disclose. The Springer Healthcare IME planners and others have nothing to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Springer Healthcare IME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until July 2025. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.